Background
Methods
Study population
Endpoints and predictor variables
Statistical analysis
Descriptive and univariable analysis
Multivariable analysis
Results
Characteristics of the study group
Patient characteristics | Mean ± standard deviation or frequency (%) |
---|---|
Age at diagnosis (years) (n = 994) | 50.4 ± 9.6 |
Body mass index (kg/m2) (n = 981) | 24.9 ± 4.1 |
Body surface area (m2) (n = 993) | 1.7 ± 0.1 |
Tumour characteristics
| |
Tumor status | 994 (100) |
- Primary tumour | 966 (97.2) |
- Relapsed tumour | 28 (2.8) |
Tumour gradea
| 979 (98.5) |
- 1 | 39 (4.0) |
- 2 | 334 (34.1) |
- 3 | 606 (61.9) |
Tumour type | 994 (100) |
- Invasive ductal carcinoma | 823 (82.8) |
- Invasive lobular carcinoma | 103 (10.4) |
- Mixed | 27 (2.7) |
- Others | 41 (4.1) |
Tumour stageb
| 978 (98.4) |
- I | 113 (11.5) |
- IIA | 306 (31.3) |
- IIB | 245 (25.1) |
- IIIA | 193 (19.7) |
- IIIB | 44 (4.5) |
- IIIC | 77 (7.9) |
Receptor status | |
- Estrogen receptor positive | 683 (68.8) |
- Progesterone receptor positive | 577 (58.1) |
- HER2 positive | 205 (20.7) |
Subtypec
| 981 (98.7) |
- Luminal A | 325 (33.1) |
- Luminal B HER2- | 234 (23.9) |
- Luminal B HER2+ | 121 (12.3) |
- HER2-like | 84 (8.6) |
- Triple negative | 217 (22.1) |
Nottingham Prognostic Index (NPI)d (n = 757) | 5.0 ± 0.9 |
Chemotherapy characteristics
| |
Chemotherapy setting | 994 (100) |
- Adjuvant | 874 (87.9) |
- Neoadjuvant | 120 (12.1) |
Planned cycles of FEC chemotherapy | 994 (100) |
- 3 cycles FEC | 559 (56.2) |
- 4 or 5 cycles FEC | 2 (0.2) |
- 6 cycles FEC | 433 (43.6) |
Relative dose intensity (RDI) (n = 994) | 0.96 ± 0.1 |
Growth factor use | 994 (100) |
- Primary | 15 (1.5) |
- Secondary | 325 (32.7) |
- None | 654 (65.8) |
Baseline laboratory parameters
| |
White blood cell count (109/L) (n = 985) | 7.2 ± 2.0 |
Absolute neutrophil count (109/L) (n = 937) | 4.4 ± 1.6 |
Haemoglobin (g/dl) (n = 989) | 13.3 ± 1.0 |
Platelets (109/L) (n = 985) | 275.4 ± 65.1 |
Total bilirubin (mg/dl) (n = 915) | 0.4 ± 0.2 |
Creatinine (mg/dl) (n = 957) | 0.8 ± 0.1 |
Alanine aminotransferase (U/L) (n = 955) | 23.3 ± 15.3 |
Aspartate aminotransferase (U/L) (n = 955) | 21.9 ± 11.1 |
FEC chemotherapy toxicities
| |
Febrile neutropenia | 166 (16.7) |
- Febrile neutropenia in first cycle | 107 (10.7) |
Prolonged (≥ 5 days) grade 4 neutropenia | 345 (34.7) |
Deep neutropenia (< 100/μl) | 93 (9.4) |
Other grade 3–4 toxicities | 46 (4.6) |
Genotype | ||||||
---|---|---|---|---|---|---|
Gene | n | GG | GA | AA | CC | CA |
n (%) | n (%) | n (%) | n (%) | n (%) | ||
ABCC2/MRP2rs8187710 | 954 | 842 (88.3) | 110 (11.5) | 2 (0.2) | ||
ABCG2/BRCPrs2231137 | 955 | 888 (93.0) | 67 (7.0) | |||
CYP2B6rs2279343 | 910 | 57 (6.2) | 382 (42.0) | 471 (51.8) | ||
CYP2C8rs72558196 | 960 | 960 (100) | ||||
CYP2C9rs1057910 | 954 | 853 (89.4) | 3 (0.3) | 98 (10.3) | ||
CYP2C19rs4244285 | 946 | 652 (68.9) | 266 (28.1) | 28 (3.0) | ||
CYP2C19rs4986893 | 960 | 960 (100) | ||||
CYP3A4rs2740574 | 955 | 2 (0.2) | 57 (6) | 896 (93.8) | ||
CYP3A4rs55785340 | 957 | 957 (100) | ||||
CYP3A5rs776746 | 959 | 834 (87.0) | 118 (12.3) | 7 (0.7) | ||
DPYDrs1801159 | 960 | 47 (4.9) | 267 (27.8) | 646 (67.3) | ||
DPYDrs3918290 | 949 | 945 (99.6) | 4 (0.4) | |||
DPYDrs1801160 | 957 | 853 (89.1) | 96 (10.0) | 8 (0.9) | ||
GSTA1rs3957357 | 938 | 329 (35.1) | 441 (47.0) | 168 (17.9) | ||
GSTP1rs1695 | 959 | 118 (12.3) | 452 (47.1) | 389 (40.6) | ||
MRP1rs1883112 | 956 | 295 (30.9) | 485 (50.7) | 176 (18.4) | ||
MRP1rs7853758 | 952 | 701 (73.6) | 231 (24.3) | 20 (2.1) | ||
MTHFRrs1801131 | 951 | 446 (46.9) | 92 (9.7) | 413 (43.4) | ||
UGT2B7rs12233719 | 949 | 949 (100) | ||||
UGT2B7rs7662029 | 955 | 210 (22.0) | 473 (49.5) | 272 (28.5) | ||
XPD/ERCC2rs1799793 | 954 | 412 (43.2) | 429 (45.0) | 113 (11.8) | ||
XRCC1rs25489 | 954 | 875 (91.7) | 77 (8.1) | 2 (0.2) | ||
XRCC3rs861534 | 949 | 357 (37.6) | 441 (46.5) | 151 (15.9) | ||
Gene
|
n
|
TT
|
CC
|
CT
|
AA
|
TA
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
| ||
ABCC2/MRP2rs17222723 | 951 | 843 (88.6) | 2 (0.2) | 106 (11.2) | ||
ABCC2/MRP2rs2804402 | 935 | 297 (31.8) | 185 (19.8) | 453 (48.4) | ||
CYP2B6rs8192709 | 927 | 846 (91.3) | 87 (8.7) | |||
CYP2C8rs10509681 | 960 | 740 (77.1) | 12 (1.2) | 208 (21.7) | ||
CYP2C9rs1799853 | 957 | 15 (1.6) | 712 (74.4) | 230 (24) | ||
CYP3A4rs4986910 | 959 | 938 (97.8) | 21 (2.2) | |||
DPYDrs1801265 | 960 | 635 (66.1) | 46 (4.8) | 279 (29.1) | ||
FGFR4rs351855 | 954 | 88 (9.2) | 461 (48.3) | 405 (42.5) | ||
GSTP1rs1138272 | 952 | 6 (0.6) | 778 (81.7) | 168 (17.7) | ||
MDRI/ABCB1rs1045642 | 914 | 265 (29.0) | 208 (22.8) | 441 (48.2) | ||
MRP1rs13058338 | 949 | 482 (50.8) | 67 (7.1) | 400 (42.1) | ||
MRP1rs246221 | 956 | 462 (48.3) | 71 (7.4) | 423 (44.3) | ||
MRP1rs3743527 | 930 | 13 (1.4) | 562 (60.4) | 355 (38.2) | ||
MRP1rs4673 | 954 | 115 (12.0) | 406 (42.6) | 433 (45.4) | ||
MTHFRrs1801133 | 959 | 121 (12.6) | 401 (41.8) | 437 (45.6) | ||
NQO1rs1800566 | 958 | 35 (3.6) | 605 (63.2) | 318 (33.2) | ||
UGT2B7rs7439366 | 955 | 272 (28.5) | 210 (22.0) | 473 (49.5) | ||
UGT2B7rs7668282 | 954 | 940 (98.5) | 1 (0.1) | 13 (1.4) | ||
Gene
|
n
|
GG
|
GT
|
TT
|
CC
|
CG
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
| ||
ALDH3A1rs2228100 | 934 | 67 (7.2) | 554 (59.3) | 313 (33.5) | ||
CYP2B6rs3745274 | 954 | 535 (56.1) | 365 (38.2) | 54 (5.7) | ||
GPX4rs757229 | 940 | 263 (28.0) | 212 (22.5) | 465 (49.5) | ||
MRP1rs4148350 | 957 | 847 (88.5) | 105 (11.0) | 5 (0.5) | ||
MRP1rs45511401 | 960 | 847 (88.2) | 109 (11.4) | 4 (0.4) | ||
UGT2B7rs3924194 | 954 | 19 (2.0%) | 712 (74.6) | 223 (23.4) | ||
XPD/ERCC2rs13181 | 951 | 116 (12.2) | 449 (47.2) | 386 (40.6) | ||
Gene
|
n
|
GG
|
GT
|
TT
|
GA
|
TA
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
| ||
MDRI/ABCB1rs2032582 | 948 | 283 (29.9) | 445 (46.9) | 185 (19.5) | 23 (2.4) | 12 (1.3) |
TYMSrs11280056 | 918 | AAGTTA 442 (48.2) | AAGTTA.DEL 394 (42.9) | DEL 82 (8.9) |
Univariable analysis
FN in any cycle | FN in cycle 1 | |||
---|---|---|---|---|
Variable | OR (95% CI) | p-value | OR (95% CI) | p-value |
Platelets (109/L, per 10 units change) | 0.96 (0.93; 0.98) | 0.002 | 0.95 (0.92; 0.99) | 0.005 |
ANC (109/L) | 0.87 (0.77; 0.98) | 0.023 | 0.86 (0.74; 1.00) | 0.046 |
ALT (U/L, per 10 units change) | 1.12 (1.02; 1.23) | 0.024 | - | - |
WBC (109/L) | 0.90 (0.83; 0.99) | 0.032 | 0.88 (0.79; 0.99) | 0.028 |
Height (cm) | - | - | 1.03 (1.00; 1.07) | 0.043 |
Haemoglobin (g/dl) | 0.87 (0.73; 1.02) | 0.094 | 0.80 (0.66; 0.98) | 0.030 |
Planned cycles FEC (6 vs. 3 cycles) | 1.09 (0.98; 1.22) | 0.129 | - | - |
ASTa (U/L, per 10 units change) | 1.09 (0.95; 1.24) | 0.210 | - | - |
BSA (m2) | - | - | 2.44 (0.59; 10.03) | 0.217 |
Creatinin (mg/dl) | 2.04 (0.66; 6.33) | 0.219 | - | - |
Planned dose of epirubicin (100 mg/m2) | - | - | 1.01 (0.99; 1.02) | 0.217 |
MRP1rs4148350 | 0.000 | 0.004 | ||
- GT vs. GG | 1.82 (1.12; 2.94) | 0.015 | 2.09 (1.21; 3.61) | 0.008 |
- TT vs. GG | 22.06 (2.45; 198.96) | 0.006 | 6.30 (1.04; 38.28) | 0.045 |
MRP1rs45511401b
| 0.000 | 0.004 | ||
- GT vs. GG | 1.80 (1.12; 2.89) | 0.015 | 1.82 (1.05; 3.17) | 0.034 |
- TT vs. GG | 16.40 (1.69; 158.84) | 0.016 | 9.20 (1.28; 66.20) | 0.027 |
MRP1rs246221 | 0.004 | 0.039 | ||
- TT vs. CC | 0.47 (0.25; 0.86) | 0.014 | 0.49 (0.24; 1.00) | 0.053 |
- TC vs. CC | 0.80 (0.44; 1.45) | 0.459 | 0.80 (0.40; 1.61) | 0.530 |
FGFR4rs351855 | 0.098 | - | - | |
- CT vs. CC | 1.25 (0.88; 1.77) | 0.216 | ||
- TT vs. CC | 0.60 (0.29; 1.24) | 0.166 | ||
CYP3A4rs4986910 | 0.171 | - | - | |
- TC vs. TT | 0.24 (0.03; 1.84) | |||
XRCC3rs861534 | 0.130 | 0.044 | ||
- GG vs. AA | 1.25 (0.76; 2.07) | 0.381 | 1.73 (0.91; 3.29) | 0.095 |
- GA vs. AA | 0.86 (0.52; 1.42) | 0.544 | 1.03 (0.53; 1.99) | 0.930 |
TYMSrs11280056 | 0.114 | - | - | |
- AAGTTA.DEL vs. AAGTTA | 0.88 (0.60; 1.27) | 0.486 | ||
- DEL vs. AAGTTA | 1.60 (0.91; 2.82) | 0.100 | ||
GSTP1rs1695 | 0.228 | - | - | |
- AG vs. AA | 0.75 (0.53; 1.08) | 0.124 | ||
- GG vs. AA | 0.70 (0.40; 1.25) | 0.231 | ||
GSTA1rs3957357 | - | - | 0.163 | |
- GG vs. AA | 0.95 (0.49; 1.83) | 0.875 | ||
- GA vs. AA | 1.45 (0.80; 2.65) | 0.223 | ||
ALDH3A1rs2228100 | - | - | 0.188 | |
- GG vs. CC | 1.86 (0.92; 3.76) | 0.086 | ||
- GC vs. CC | 1.27 (0.81; 1.98) | 0.297 | ||
MRP1rs1883112 | - | - | 0.187 | |
- AG vs. AA | 0.87 (0.52; 1.46) | 0.594 | ||
- GG vs. AA | 0.59 (0.32; 1.08) | 0.087 | ||
UGT2B7rs7439366 | - | - | 0.204 | |
- TT vs. CC | 1.08 (0.57; 2.04) | 0.813 | ||
- TC vs. CC | 1.52 (0.87; 2.65) | 0.139 | ||
UGT2B7rs7662029 | - | - | 0.204 | |
- GG vs. AA | 0.93 (0.49; 1.75) | 0.813 | ||
- GA vs. AA | 1.41 (0.86; 2.31) | 0.174 |
Risk factors of febrile neutropenia in any cycle
Determinant | FN in any cycle (n = 910) | FN in cycle 1 (n = 937) | ||
---|---|---|---|---|
Odds ratio (95% CI) |
p-value | Odds ratio (95% CI) |
p-value | |
Platelets (109/L, per 10 units change) | 0.952 (0.923; 0.981) | 0.001 | 0.951 (0.917; 0.985) | 0.006 |
Hb (g/dl) | 0.812 (0.673; 0.978) | 0.029 | 0.001 (<0.001; 0.194) | 0.009 |
Height (cm) | - | - | 0.617 (0.414; 0.919) | 0.018 |
Interaction (height and Hb)a
| - | - | 1.040 (1.008; 1.072) | 0.012 |
ALT (U/L, per 10 unit change) | 1.173 (1.056; 1.303) | 0.003 | - | - |
MRP1rs4148350 | 0.019 | 0.006 | ||
- GTb vs. GG | 1.494 (0.890; 2.507) | 0.129 | 2.149 (1.226; 3.768) | 0.008 |
- TTc vs. GG | 17.13 (1.72; 170.90) | 0.016 | 6.696 (1.039; 43.167) | 0.046 |
MRP1rs246221 | 0.023 | - | - | |
- TTd vs. CC | 0.501 (0.259; 0.969) | 0.040 | ||
- TC vs. CC | 0.805 (0.423; 1.533) | 0.510 | ||
FGFR4rs351855 | 0.062 | - | - | |
-CT vs. CC | 1.253 (0.862; 1.821) | 0.238 | ||
-TTe vs. CC | 0.505 (0.230; 1.113) | 0.090 |